share_log

Arcutis Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Moore Matthew Richard

SEC announcement ·  Feb 15 18:53
Summary by Moomoo AI
Matthew Richard Moore, SVP and Chief Business Officer of Arcutis Biotherapeutics, acquired a total of 70,398 shares of common stock on February 13, 2024, as per the latest SEC filings. These transactions were classified as 'Grant, award or other acquisition' under transaction code 'A'. Following these acquisitions, Moore's direct holdings in the company increased to 149,488 shares. The transactions occurred on a single day, with multiple grants ranging from 4,166 to 26,666 shares each. The acquisitions reflect a strengthening of Moore's investment in the company, signaling potential confidence in Arcutis Biotherapeutics' future prospects.
Matthew Richard Moore, SVP and Chief Business Officer of Arcutis Biotherapeutics, acquired a total of 70,398 shares of common stock on February 13, 2024, as per the latest SEC filings. These transactions were classified as 'Grant, award or other acquisition' under transaction code 'A'. Following these acquisitions, Moore's direct holdings in the company increased to 149,488 shares. The transactions occurred on a single day, with multiple grants ranging from 4,166 to 26,666 shares each. The acquisitions reflect a strengthening of Moore's investment in the company, signaling potential confidence in Arcutis Biotherapeutics' future prospects.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more